<DOC>
	<DOCNO>NCT00876304</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics multiple ascend dos PF-04802540 administer orally subject schizophrenia .</brief_summary>
	<brief_title>Multiple Dose Safety Study PF-04802540 Subjects With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Males female nonchildbearing capacity age 18 55 year inclusive DSMIV diagnosis schizophrenia , stable symptom least 3 month Body mass index range 18 40 kg/m2 body weight &gt; 45 kg . Evidence history primary DSM IV axis I diagnosis schizophrenia . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease Any condition possibly affect drug absorption ( eg , gastrectomy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>PF-04802540 multiple dose safety study</keyword>
</DOC>